Julie Allickson, PhD

Julie Allickson, PhD serves as Chief, Manufacturing Development Center Officer for the Wake Forest Institute for Regenerative Medicine. Dr. Allickson has 30 years of experience in clinical translation of cellular therapies and regenerative medicine products including business management and board directorship experience. Dr. Allickson has 8 years’ experience as an executive officer with a publicly traded company building services for cellular banking including licensure of technology with more than 30 affiliates.  An experienced scientist leader delivering innovation, driving milestones, maintain sensitivity to financial considerations, building multidisciplinary teams, strategic planning, program management, and regulatory expertise.

Dr. Allickson is Director of the Regenerative Medicine Clinical Center at Wake Forest Institute for Regenerative Medicine. She heads the clinical translation team streamlining development to create a robust pipeline of products in development and early phase clinical trials including cell therapy, gene therapy, tissue engineered organs and tissues, biomaterials and devices. Translation begins at Proof-of-Concept where early discussion with regulators and clinicians are critical in moving the technology from the bench to the bedside.  Prior to the Institute, Dr. Allickson was the Vice President of Research and Development and Laboratory Operations for Cryo-Cell International Inc.

Dr. Allickson was part of the team to perform the first Bone Marrow Transplant at the University of Miami in 1990 and at Miami Children’s Hospital Bone Marrow Transplant Program. She has a Doctorate in Health Sciences- Clinical Immunology along with a Master’s Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy and a member of the American Association of Blood Banks (AABB).  Dr. Allickson is on the Board of Directors for AABB and IWEUS Capital along with Regenerative Medicine Outcomes Foundation as a scientific advisor, Editorial board of CELLR4, Vice Chair for Cord Blood Association Quality Committee, Technical Advisory Board for Tissue Engineered Products under ICCBBA, grant reviewer for state funded initiatives such as CIRM and serves on the ISCT Commercialization Committee.